Previous close | 1.5000 |
Open | 1.5000 |
Bid | 0.0000 |
Ask | 1.8500 |
Strike | 20.00 |
Expiry date | 2024-05-17 |
Day's range | 1.5000 - 1.5000 |
Contract range | N/A |
Volume | |
Open interest | 93 |
Despite Revenue Near Estimates, Losses Exceed Expectations
EL MONTE, Calif., May 03, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.
EL MONTE, Calif., April 11, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.